Taysha Gene Therapies (TSHA) Capital Expenditures (2020 - 2026)

Taysha Gene Therapies has disclosed Capital Expenditures across 7 years of filings, most recently posting $24000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $24000.0, down 93.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $384000.0 (up 35.21% YoY), and the FY2025 annual result was $738000.0, up 1504.35% from the prior year.
• Capital Expenditures came in at $24000.0 for Q1 2026 at Taysha Gene Therapies, down from $713000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $16.3 million in Q2 2022 to a low of -$3.4 million in Q3 2023.
• The 5-year median for Capital Expenditures is $140000.0 (2024), against an average of $1.5 million.
• Across the five-year window, Capital Expenditures soared 18471.43% in 2023 and slumped 459.42% in 2025, its largest moves.
• Taysha Gene Therapies' Capital Expenditures stood at $2.3 million in 2022, then jumped by 49.24% to $3.4 million in 2023, then sank by 109.58% to -$330000.0 in 2024, then soared by 316.06% to $713000.0 in 2025, then plunged by 96.63% to $24000.0 in 2026.
• The last three Capital Expenditures figures came in at $24000.0 (Q1 2026), $713000.0 (Q4 2025), and -$386000.0 (Q3 2025), per Business Quant data.